New Trial for Potential Lupus of the Skin Treatment

Rigel Pharmaceuticals, Inc. began a new Phase 1 clinical trial
looking at a potential treatment for discoid lupus (lupus of the skin). Applied to the skin, R333 may be useful in treating acute and chronic phases of this potentially disfiguring disorder.  R333 is a JAK/SYK inhibitor, which means it may inhibit Januse Kinase (JAK) and Spleen Tyrosine Kinase(Syk), both of which play a part in regulating inflammation. For more information, check Rigel Pharmaceutical's website at

Full Story